盐酸地美环素结构式
|
常用名 | 盐酸地美环素 | 英文名 | Demeclocycline hydrochloride |
---|---|---|---|---|
CAS号 | 64-73-3 | 分子量 | 501.314 | |
密度 | N/A | 沸点 | 795.9ºC at 760 mmHg | |
分子式 | C21H22Cl2N2O8 | 熔点 | >245°C (dec.) | |
MSDS | 中文版 美版 | 闪点 | 435.2ºC | |
符号 |
GHS07 |
信号词 | Warning |
盐酸地美环素用途Demeclocycline盐酸盐是四环素类抗生素,对莱姆病,粉刺和支气管炎有效。 |
中文名 | 地美环素盐酸盐 |
---|---|
英文名 | demeclocycline hydrochloride |
中文别名 | 盐酸去甲金霉素 | 盐酸地美环素 | 盐酸去甲基金霉素 |
英文别名 | 更多 |
沸点 | 795.9ºC at 760 mmHg |
---|---|
熔点 | >245°C (dec.) |
分子式 | C21H22Cl2N2O8 |
分子量 | 501.314 |
闪点 | 435.2ºC |
精确质量 | 500.075317 |
PSA | 181.62000 |
LogP | 1.76720 |
外观性状 | 黄色固体 |
储存条件 | 本品应密封于阴凉干燥处避光保存。 |
水溶解性 | H2O: 20 mg/mL, clear, very deep greenish yellow |
计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:7 3.氢键受体数量:9 4.可旋转化学键数量:2 5.互变异构体数量:132 6.拓扑分子极性表面积182 7.重原子数量:33 8.表面电荷:0 9.复杂度:961 10.同位素原子数量:0 11.确定原子立构中心数量:5 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:2 |
更多 | 1. 性状:粉状 2. 密度(g/mL,25/4℃):不确定 3. 相对蒸汽密度(g/mL,空气=1):不确定 4. 熔点(ºC):> 245°C (dec.) 5. 沸点(ºC,常压):不确定 6. 沸点(ºC, 5.2kPa):不确定 7. 折射率:不确定 8. 闪点(ºC):不确定 9. 比旋光度(º):不确定 10. 自燃点或引燃温度(ºC):不确定 11. 蒸气压(kPa,25ºC):不确定 12. 饱和蒸气压(kPa,60ºC):不确定 13. 燃烧热(KJ/mol):不确定 14. 临界温度(ºC):不确定 15. 临界压力(KPa):不确定 16. 油水(辛醇/水)分配系数的对数值:不确定 17. 爆炸上限(%,V/V):不确定 18. 爆炸下限(%,V/V):不确定 19. 溶解性:H2O: 20mg/mL, clear, very deep greenish yellow |
盐酸地美环素毒理学数据: 急性毒性:人口经 LDLo : 69 mg/kg/4D-I ;大鼠口经 LD50 : 2372 mg/kg ;大鼠静脉LD50:94 mg/kg; 小鼠口经LD50:2150 mg/kg;小鼠静脉LD50:275 mg/kg; 繁殖:大鼠子宫TDLo:50 mg/kgSEX/DURATION : female 1 day(s) pre-mating; 妇女途径未知TDLo:48 ug/kgSEX/DURATION : female 28 week(s) after conception; |
Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.
Bioorg. Med. Chem. Lett. 22 , 1709-11, (2012) Over-expressions of miRNAs are being increasingly linked with many diseases including different types of cancer. In this study, the role of some known small molecular therapeutics has been investigate... |
|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Chem. Res. Toxicol. 23 , 1215-22, (2010) Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals ... |
|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug Metab. Dispos. 38 , 2302-8, (2010) Drug-induced liver injury (DILI) is one of the most important reasons for drug development failure at both preapproval and postapproval stages. There has been increased interest in developing predicti... |
2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-, hydrochloride (1:1) |
Ledermycin hydrochloride |
EINECS 200-592-2 |
Demeclocycline hydrochloride |
(4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide,hydrochloride |
(4S,4aS,5aS,6S,12aS)-7-chloro-4-(diméthylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotétracène-2-carboxamide chlorhydrate |
demeclocycline hydrochloride [INN_en] |
(4S,4aS,5aS,6S,12aS)-7-Chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-tetracenecarboxamide hydrochloride (1:1) |
(4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride |
(4S,4aS,5aS,6S,12aS)-7-Chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride (1:1) |
(4S,4aS,5aS,6S,12aS)-7-Chlor-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-carboxamidhydrochlorid |
2-naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-, monohydrochloride |
MFCD00864922 |
Demeclocycline (hydrochloride) |